




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 403/06, A61K 31/40, C07D 409/14, 403/14, 405/14		A1	(11) International Publication Number: WO 00/35909
			(43) International Publication Date: 22 June 2000 (22.06.00)
(21) International Application Number: PCT/EP99/09673		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 9 December 1999 (09.12.99)			
(30) Priority Data: 60/112,590 17 December 1998 (17.12.98) US 60/149,028 16 August 1999 (16.08.99) US			
(71) Applicant: F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, CH-4070 Basle (CH).			
(72) Inventors: CORBETT, Wendy, Lea; 36 Ridgewood Drive, Randolph, NJ 07869-3754 (US). LUK, Kin-Chun; 66 Evergreen Drive, North Caldwell, NJ 07006-4622 (US). MAHANEY, Paige, E.; 243 Country Club Lane, Scotch Plains, NJ 07076 (US).			
(74) Agent: LOESCHNER, Thomas; Grenzacherstrasse 124, CH-4070 Basle (CH).		<p>Published</p> <p><i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
(54) Title: 4-ARYLOXINDOLES AS INHIBITORS OF JNK PROTEIN KINASES			
<div style="text-align: center;"> <p>(I)</p> </div>			
(57) Abstract			
<p>Novel 4-aryloxindoles having formula (I), where, R², R³, X and A as set forth in the specification inhibit or modulate protein kinases, in particular JNK protein kinases and are useful as anti-inflammatory agents, particularly in the treatment of rheumatoid arthritis.</p>			

CLAIMS

What Is Claimed Is:

1. A compound of the formula



and the pharmaceutically acceptable salts of the foregoing compounds,
wherein

- A is aryl or heteroaryl, each of which optionally substituted by one or more -OR⁴, -COR⁴, -COOR⁴, -CONR⁶R⁷, -NR⁶R⁷, -CN, -NO₂, -SO₂R⁴, -SO₂NR⁶R⁷, halogen, perfluoroalkyl, lower alkyl, lower alkyl substituted by (a), halogen, cycloalkyl, and/or heterocycle; cycloalkyl or cycloalkyl substituted by (a), halogen, lower alkyl, and/or heterocycle; heterocycle or heterocycle substituted by (a), halogen, lower alkyl, and/or cycloalkyl;
where (a) is -OR⁴, -NR⁶R⁷, -COR⁴, -COOR⁴, -OCOR⁴, -CONR⁶R⁷, -CN, -NO₂, -SO₂R⁴, or -SO₂NR⁶R⁷;

- R² is hydrogen, -OR⁴, -COOR⁴, -CONR⁶R⁷, -NR⁶R⁷, halogen, -NO₂, -CN, -SO₂NR⁶R⁷, -SO₂R⁴ perfluoroalkyl, lower alkyl, or lower alkyl substituted by -OR⁸, -NR⁶R⁷, -COR⁴, -COOR⁴, and/or -CONR⁶R⁷;

R³ is hydrogen, -OR⁴, -COR⁴, -COOR⁴, -CONR⁶R⁷, halogen, -CN, -NR⁶R⁷, perfluoroalkyl, lower alkyl, or lower alkyl substituted by -OR⁸ and/or -NR⁶R⁷;

R^4 is hydrogen, lower alkyl or lower alkyl substituted by (b), cycloalkyl and/or heterocycle; cycloalkyl or cycloalkyl substituted (b), lower alkyl and/or heterocycle; heterocycle or heterocycle substituted by (b), lower alkyl and/or cycloalkyl;
5 where (b) is $-OR^5$, $-COOR^8$, $-COR^8$, $-CONR^8R^9$, $-NR^6R^7$, $-CN$, $-NO_2$, $-SO_2R^8$, or $-SO_2NR^8R^9$;

R^5 is hydrogen, $-COR^8$, $-CONR^8R^9$, lower alkyl or lower alkyl substituted by $-OR^9$, $-NR^9R^{10}$, $-N(COR^9)R^{10}$, $-COR^9$, $-CONR^9R^{10}$, and/or $-COOR^9$;

10

R^6 and R^7 are each independently hydrogen, $-COR^8$, $-COOR^8$, $-CONR^8R^9$, $-SO_2R^8$, $-SO_2NR^8R^9$, lower alkyl or lower alkyl substituted by cycloalkyl (or cycloalkyl substituted by (c), lower alkyl and/or heterocycle), heterocycle (or heterocycle substituted by (c), lower alkyl and/or cycloalkyl), aryl (or aryl substituted by (c), lower alkyl, cycloalkyl and/or heterocycle), or heteroaryl (or heteroaryl substituted by (c), lower alkyl, cycloalkyl and/or heterocycle); or

15

R^6 and R^7 are each independently cycloalkyl or cycloalkyl substituted by (c), lower alkyl and/or heterocycle;

heterocycle (or heterocycle substituted by (c), lower alkyl and/or cycloalkyl),

20

aryl (or aryl substituted by (c), lower alkyl, cycloalkyl and/or heterocycle), or heteroaryl (or heteroaryl substituted by (c), lower alkyl, cycloalkyl and/or heterocycle); where (c) is $-OR^5$, $-COOR^8$, $-COR^8$, $-CONR^8R^9$, $-CN$, $-NO_2$, $-SO_2R^8$, $-SO_2NR^8R^9$, $-NR^8R^9$;

25

or alternatively, $-NR^6R^7$ forms a ring having 3 to 7 atoms, said ring optionally including one or more additional hetero atoms and being optionally substituted by one or more of lower alkyl, $-OR^5$, $-COR^8$, $-COOR^8$, $-CONR^8R^9$, and $-NR^5R^9$;

30

R^8 is hydrogen, lower alkyl (or lower alkyl substituted by cycloalkyl, heterocycle, aryl, heteroaryl, $-OR^9$, $-NR^9R^{10}$, and/or $-N(COR^9)R^{10}$),

aryl (or aryl substituted by (d), lower alkyl, cycloalkyl, heterocycle, halogen and/or $-\text{SO}_2\text{F}$),

heteroaryl (or heteroaryl substituted by (d), lower alkyl, cycloalkyl, heterocycle, halogen and/or $-\text{SO}_2\text{F}$),

- 5 cycloalkyl (or cycloalkyl substituted by (d), lower alkyl, heterocycle and/or aryl), or heterocycle (or heterocycle substituted by (d), lower alkyl, cycloalkyl and/or aryl); where (d) is $-\text{OR}^9$, $-\text{COOR}^9$, $-\text{COR}^9$, $-\text{CONR}^{10}\text{R}^9$, $-\text{NR}^{10}\text{R}^9$, $-\text{CN}$, $-\text{NO}_2$, $-\text{SO}_2\text{R}^9$, or $-\text{SO}_2\text{NR}^{10}\text{R}^9$;

- 10 R^9 and R^{10} are each independently hydrogen, lower alkyl or aryl; and

X is $=\text{N}-$ or $=\text{CH}-$.


2. The compounds of claim 1, wherein

- 15 R^8 is hydrogen, lower alkyl optionally substituted by cycloalkyl, heterocycle, aryl, heteroaryl, $-\text{OR}^9$, $-\text{NR}^9\text{R}^{10}$, and/or $-\text{N}(\text{COR}^9)\text{R}^{10}$;
 aryl optionally substituted by the group consisting of (d), lower alkyl, cycloalkyl and/or heterocycle;
 heteroaryl optionally substituted by (d), lower alkyl, cycloalkyl and/or heterocycle;
 20 cycloalkyl optionally substituted by (d), lower alkyl, heterocycle and/or aryl;
 heterocycle optionally substituted by (d), lower alkyl, cycloalkyl and/or aryl;
 where (d) is $-\text{OR}^9$, $-\text{COOR}^9$, $-\text{COR}^9$, $-\text{CONR}^{10}\text{R}^9$, $-\text{NR}^{10}\text{R}^9$, $-\text{CN}$, $-\text{NO}_2$, $-\text{SO}_2\text{R}^9$, or $-\text{SO}_2\text{NR}^{10}\text{R}^9$;
 R^9 and R^{10} are each independently hydrogen or lower alkyl;
 25 and R^2 , R^3 , A and X are as in claim 1.

3. The compounds of claim 1 or 2 wherein A is aryl or heteroaryl each of which optionally is substituted by $-\text{NR}^6\text{R}^7$, $-\text{OR}^4$, $-\text{COR}^4$, $-\text{COOR}^4$, $-\text{CONR}^6\text{R}^7$, $-\text{SO}_2\text{R}^4$, $-\text{SO}_2\text{NR}^6\text{R}^7$, lower alkyl and/or lower alkyl substituted by $-\text{OR}^5$, $-\text{NR}^6\text{R}^7$, $-\text{COR}^4$, $-\text{COOR}^4$, and/or $-\text{CONR}^6\text{R}^7$.
- 30

81

4. The compounds of claim 1 having the formula:



and the pharmaceutically acceptable salts thereof wherein

- 5 R¹, R¹' and R¹'' are each independently hydrogen, -OR⁴, -COR⁴, -COOR⁴, -CONR⁶R⁷, -NR⁶R⁷, -CN, -NO₂, -SO₂R⁴, -SO₂NR⁶R⁷, halogen, perfluoroalkyl, lower alkyl (or lower alkyl substituted by (a), halogen, cycloalkyl, and/or heterocycle), cycloalkyl (or cycloalkyl substituted by (a), halogen, lower alkyl, and/or heterocycle), heterocycle (or heterocycle substituted by (a), halogen, lower alkyl, and/or cycloalkyl);
- 10 where (a) is -OR⁴, -NR⁶R⁷, -COR⁴, -COOR⁴, -OCOR⁴, -CONR⁶R⁷, -CN, -NO₂, -SO₂R⁴, or -SO₂NR⁶R⁷;
- and R², R³, R⁶, R⁷ and X are as defined in claim 1 for formula I.

5. The compounds of any one of claims 1 to 4 wherein R² is hydrogen, -OR⁴, -NO₂, -NR⁶R⁷, perfluoroalkyl, halogen, -COR⁴, -COOR⁴, -CONR⁶R⁷ lower alkyl and/or lower alkyl substituted by -OR⁸ and/or -NR⁶R⁷.
- 15

6. The compounds of any one of claims 1 to 5 wherein R³ is hydrogen, -OR⁴, -NR⁶R⁷, lower alkyl and/or lower alkyl substituted by the group consisting of -OR⁸ and -NR⁶R⁷.
- 20

7. The compounds of any one of claims 1 to 6 wherein R⁴ is selected from the group consisting of -H and lower alkyl which optionally may be substituted by the group consisting of -OR⁵, -COOR⁸, -COR⁸, -NR⁶R⁷ and -CONR⁸R⁹.

8. The compounds of any one of claims 1 to 7 wherein R^5 is selected from the group consisting of $-\text{COR}^8$, $-\text{CONR}^8\text{R}^9$, and lower alkyl.
9. The compounds of any one of claims 1 to 8 wherein R^6 and R^7 are each independently selected from the group consisting of $-\text{H}$, $-\text{COR}^8$, $-\text{COOR}^8$, $-\text{CONR}^8\text{R}^9$, $-\text{SO}_2\text{R}^8$, aryl, heteroaryl and lower alkyl which optionally may be substituted by the group consisting of OR^5 , and $-\text{NR}^8\text{R}^9$.
10. The compounds of any one of claims 1 to 9 wherein R^8 is selected from the group consisting of $-\text{H}$, aryl, heteroaryl and lower alkyl which optionally may be substituted by the group consisting of aryl, heteroaryl, $-\text{OR}^9$, $-\text{NR}^9\text{R}^{10}$, and $-\text{N}(\text{COR}^9)\text{R}^{10}$.
11. The compounds of any one of claims 1 to 10 wherein X is $=\text{CH}-$.
12. The compound of claim 1 or 2 wherein A is heteroaryl.
13. The compound of claim 12 wherein A is indole or substituted indole.
14. A compound of claim 5 which is
- (Z)-1,3-Dihydro-4-phenyl-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one;
(Z)-4-(3-Aminophenyl)-1,3-dihydro-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one;
(Z)-4-(3-Aminophenyl)-1,3-dihydro-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one hydrochloride salt;
- (Z)-1,3-Dihydro-4-(4-methoxyphenyl)-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one;
(Z)-1,3-Dihydro-4-(3-nitrophenyl)-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one;
(Z)-1,3-Dihydro-3-[(1H-pyrrol-2-yl)methylene]-4-(3-trifluoromethylphenyl)-2H-indol-2-one;

(Z)-1,3-Dihydro-4-(4-methylphenyl)-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one ;

(Z)-1,3-Dihydro-4-(2-methylphenyl)-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one;

5 (Z)-4-(2,4-Dichlorophenyl)-1,3-dihydro-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one;

(Z)-4-(4-Chlorophenyl)-1,3-dihydro-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one;

10 (Z)-1,3-Dihydro-4-(2-methoxyphenyl)-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one;

(Z)-1,3-Dihydro-4-(1-naphthalenyl)-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one;

(Z)-4-(3-Chlorophenyl)-1,3-dihydro-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one;

15 (Z)-1,3-Dihydro-4-(4-hydroxyphenyl)-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one;

(Z)-4-(3-Aminophenyl)-1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2H-indol-2-one;

20 (Z)-1,3-Dihydro-4-phenyl-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2H-indol-2-one; or

(Z)-1,3-Dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2H-indol-2-one.

15. A compound of claim 5 which is

25 (Z)-4-[2,3-Dihydro-2-oxo-3-[(1H-pyrrol-2-yl)methylene]-1H-indol-4-yl]-benzoic acid;

(Z)-3-[2,3-Dihydro-2-oxo-3-[(1H-pyrrol-2-yl)methylene]-1H-indol-4-yl]-benzoic acid;

30 (Z)-4-[2,3-Dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-4-yl]-benzoic acid;

(Z)-4-[2,3-Dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-2-oxo-1H-indol-4-yl]-benzoic acid methyl ester;

(Z)-4-[5-Amino-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-4-yl]-benzoic acid methyl ester;

5 (Z)-4-[2,3-Dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-5-[(2-thienylacetyl)amino]-1H-indol-4-yl]-benzoic acid methyl ester;

(Z)-4-[2,3-Dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-5-[(2-thienylacetyl)amino]-1H-indol-4-yl]-benzoic acid;

10 (Z)-4-[2,3-Dihydro-5-fluoro-3-[(4-methyl-1H-imidazol-5-yl)methylene]-2-oxo-1H-indol-4-yl]-benzoic acid methyl ester trifluoroacetate salt;

16. A compound of claim 5 which is

(Z)-N-[3-[2,3-Dihydro-2-oxo-3-[(1H-pyrrol-2-yl)methylene]-1H-indol-4-yl]-phenyl]-4-hydroxybenzamide;

15 (Z)-N-[3-[2,3-Dihydro-2-oxo-3-[(1H-pyrrol-2-yl)methyl]ene]-1H-indol-4-yl]-phenyl]-3-bromobenzamide;

(Z)-N-[3-[2,3-Dihydro-2-oxo-3-[(1H-pyrrol-2-yl)methyl]ene]-1H-indol-4-yl]-phenyl]-3-cyanobenzamide;

20 (Z)-N-[3-[2,3-Dihydro-2-oxo-3-[(1H-pyrrol-2-yl)methylene]-1H-indol-4-yl]-phenyl]-3-nitrobenzamide;

(Z)-N-[3-[2,3-Dihydro-2-oxo-3-[(1H-pyrrol-2-yl)methylene]-1H-indol-4-yl]-phenyl]-4-fluorobenzamide;

(Z)-N-[3-[2,3-Dihydro-2-oxo-3-[(1H-pyrrol-2-yl)methylene]-1H-indol-4-yl]-phenyl]-4-nitrobenzamide;

25 (Z)-N-[3-[2,3-Dihydro-2-oxo-3-[(1H-pyrrol-2-yl)methylene]-1H-indol-4-yl]-phenyl]-4-methoxybenzamide;

(Z)-4-Amino-N-[3-[2,3-dihydro-2-oxo-3-[(1H-pyrrol-2-yl)methylene]-1H-indol-4-yl]phenyl]cyclohexanecarboxamide;

30 (Z)-N-[3-[2,3-Dihydro-2-oxo-3-[(1H-pyrrol-2-yl)methylene]-1H-indol-4-yl]-phenyl]-4-(fluorosulfonyl)benzamide; or

(Z)-N-[2-[[3-[2,3-Dihydro-2-oxo-3-[(1H-pyrrol-2-yl)methylene]-1H-indol-4-yl]phenyl]amino]-2-oxoethyl]-4-(fluorosulfonyl)benzamide;

17. A compound of claim 12 which is

(Z)-1,3-Dihydro-3-[(1H-pyrrol-2-yl)methylene]-4-(2-thiophenyl)-2H-indol-2-one;

(Z)-1,3-Dihydro-4-(2,4-dimethoxy-6-pyrimidinyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2H-indol-2-one;

(Z)-1,3-Dihydro-4-(5-indolyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2H-indol-

2-one;

(Z)-1,3-Dihydro-4-(5-indolyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-

2H-indol-2-one,

(Z)-5-Amino-1,3-dihydro-4-(5-indolyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-

2H-indol-2-one,

(Z)-N-[2,3-Dihydro-4-(5-indolyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-

oxo-1H-indol-5-yl]-2-thiopheneacetamide;

(Z)-1,3-Dihydro-4-(4-indolyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2H-indol-

2-one;

(Z)-1,3-Dihydro-4-(6-indolyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2H-indol-

2-one;

(Z)-1,3-Dihydro-4-(6-indolyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-

2H-indol-2-one,

(Z)-5-Amino-1,3-dihydro-4-(6-indolyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-

2H-indol-2-one, or

(Z)-N-[2,3-Dihydro-4-(6-indolyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-

oxo-1H-indol-5-yl]-2-thiopheneacetamide.

18. A compound of claim 5 which is

(Z)-N-[3-[2,3-Dihydro-2-oxo-3-[(1H-pyrrol-2-yl)methylene]-1H-indol-4-

yl]phenyl]methanesulfonamide;

(Z)-N-[3-[2,3-Dihydro-2-oxo-3-[(1H-pyrrol-2-yl)methylene]-1H-indol-4-

yl]phenyl]-2-thiophenesulfonamide; or

(Z)-N-[3-[2,3-Dihydro-2-oxo-3-[(1H-pyrrol-2-yl)methylene]-1H-indol-4-yl]phenyl]-4-(phenylsulfonyl)-2-thiophenesulfonamide.

19. A compound of claim 5 which is

5 (Z)-1,3-Dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-2H-indol-2-one;

(Z)-1,3-Dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-4-phenyl-2H-indol-2-one;

10 (Z)-N-[2,3-Dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-4-phenyl-1H-indol-5-yl]-2-thiopheneacetamide;

(Z)-5-Amino-1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2H-indol-2-one;

(Z)-N-[2,3-Dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-5-yl]-2-thiopheneacetamide;

15 (Z)-5-Amino-1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-4-phenyl-2H-indol-2-one;

(Z)-1,3-Dihydro-3-[(4-methyl-1H-imidazol-5-yl)methylene]-5-nitro-4-phenyl-2H-indol-2-one; or

20 (Z)-1,3-Dihydro-5-fluoro-4-(4-hydroxyphenyl)-3-[(4-methyl-1H-imidazol-5-yl)methylene]-2H-indol-2-one trifluoroacetate salt.

20. A compound of claim 1 which is

25 (Z)-1,3-Dihydro-5-fluoro-4-(4-methoxyphenyl)-3-[(4-methyl-1H-imidazol-5-yl)methylene]-2H-indol-2-one trifluoroacetate salt;

(Z)-1,3-Dihydro-4-(3,4-dimethoxyphenyl)-5-fluoro-3-[(4-methyl-1H-imidazol-5-yl)methylene]-2H-indol-2-one;

(Z)-1,3-Dihydro-4-(2,4-dimethoxyphenyl)-5-fluoro-3-[(4-methyl-1H-imidazol-5-yl)methylene]-2H-indol-2-one;

30 (Z)-4-(1,3-Benzodioxol-5-yl)-1,3-dihydro-5-fluoro-3-[(4-methyl-1H-imidazol-5-yl)methylene]-2H-indol-2-one trifluoroacetate salt;

(Z)-4-(3-Aminophenyl)-1,3-dihydro-5-fluoro-3-[(4-methyl-1H-imidazol-5-yl)methylene]-2H-indol-2-one;

(Z)-4-(3-Amino-4-methyl-phenyl)-1,3-dihydro-5-fluoro-3-[(4-methyl-1H-imidazol-5-yl)methylene]-2H-indol-2-one;

5 (Z)-1,3-Dihydro-5-fluoro-4-(3-hydroxyphenyl)-3-[(4-methyl-1H-imidazol-5-yl)methylene]-2H-indol-2-one;

(Z)-1,3-Dihydro-5-fluoro-4-(4-hydroxyphenyl)-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one;

10 (Z)-1,3-Dihydro-5-fluoro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2H-indol-2-one;

2-[3-[5-Fluoro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-2,3-dihydro-1H-indol-4-yl]-phenylamino]-acetamide; or

(Z)-1,3-Dihydro-5-fluoro-4-(4-hydroxymethyl-3-methoxy-phenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2H-indol-2-one.

15 21. (Z)-1,3-Dihydro-4-iodo-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one

22. A pharmaceutical composition comprising as an active ingredient a compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

20 23. The compounds of claim 1 for use as medicaments.

24. The use of a compound of claim 1 in the preparation of a medicament containing a compound of claim 1 for treating a neuro-degenerative disease, particularly rheumatoid arthritis.

25 25. The novel compounds, compositions and use as hereinbefore described, especially with reference to the Examples.

INTERNATIONAL SEARCH REPORT

In National Application No
PCT/EP 99/09673

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D403/06 A61K31/40

C07D409/14

C07D403/14

C07D405/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category * Citation of document, with indication, where appropriate, of the relevant passages

Relevant to claim No.

A

WO 96 40116 A (SUGEN, INC.)
19 December 1996 (1996-12-19)
cited in the application
page 1 -page 2; claim 1

1,22

A

WO 96 32380 A (PHARMACIA S.P.A.)
17 October 1996 (1996-10-17)
cited in the application
claims

1,22

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

19 April 2000

Date of mailing of the international search report

02/05/2000

Name and mailing address of the ISA
European Patent Office, P.B. 5618 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Van Bijlen, H

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l. Application No
PCT/EP 99/09673

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9640116 A	19-12-1996	US 5880141 A	09-03-1999
		AU 706597 B	17-06-1999
		AU 6044196 A	30-12-1996
		BR 9606410 A	30-12-1997
		CA 2192797 A	19-12-1996
		DE 29623744 U	30-09-1999
		EP 0769947 A	02-05-1997
		EP 0934931 A	11-08-1999
		HU 9701694 A	28-06-1999
		JP 2000026412 A	25-01-2000
		JP 10504323 T	28-04-1998
		NO 965377 A	12-02-1997
		NZ 310109 A	28-01-1999
		US 5792783 A	11-08-1998
		US 5883116 A	16-03-1999
		US 5834504 A	10-11-1998
		US 5886020 A	23-03-1999
		US 5883113 A	16-03-1999
WO 9632380 A	17-10-1996	EP 0764152 A	26-03-1997
		JP 10501821 T	17-02-1998
		US 5849710 A	15-12-1998